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Abstract
Background: We aimed to define the clinical and variant spectrum and to provide novel molecular insights into
the DHX30-associated neurodevelopmental disorder.
Methods: Clinical and genetic data from affected individuals were collected through Facebook-based family
support group, GeneMatcher, and our network of collaborators. We investigated the impact of novel missense
variants with respect to ATPase and helicase activity, stress granule (SG) formation, global translation, and their
effect on embryonic development in zebrafish. SG formation was additionally analyzed in CRISPR/Cas9-mediated
DHX30-deficient HEK293T and zebrafish models, along with in vivo behavioral assays.
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Results: We identified 25 previously unreported individuals, ten of whom carry novel variants, two of which are
recurrent, and provide evidence of gonadal mosaicism in one family. All 19 individuals harboring heterozygous
missense variants within helicase core motifs (HCMs) have global developmental delay, intellectual disability, severe
speech impairment, and gait abnormalities. These variants impair the ATPase and helicase activity of DHX30, trigger
SG formation, interfere with global translation, and cause developmental defects in a zebrafish model. Notably, 4
individuals harboring heterozygous variants resulting either in haploinsufficiency or truncated proteins presented
with a milder clinical course, similar to an individual harboring a de novo mosaic HCM missense variant.
Functionally, we established DHX30 as an ATP-dependent RNA helicase and as an evolutionary conserved factor in
SG assembly. Based on the clinical course, the variant location, and type we establish two distinct clinical subtypes.
DHX30 loss-of-function variants cause a milder phenotype whereas a severe phenotype is caused by HCM missense
variants that, in addition to the loss of ATPase and helicase activity, lead to a detrimental gain-of-function with
respect to SG formation. Behavioral characterization of dhx30-deficient zebrafish revealed altered sleep-wake activity
and social interaction, partially resembling the human phenotype.
Conclusions: Our study highlights the usefulness of social media to define novel Mendelian disorders and exemplifies
how functional analyses accompanied by clinical and genetic findings can define clinically distinct subtypes for ultra-
rare disorders. Such approaches require close interdisciplinary collaboration between families/legal representatives of
the affected individuals, clinicians, molecular genetics diagnostic laboratories, and research laboratories.
Background
RNA helicases (RH) are highly specialized proteins which
use ATP hydrolysis for the unwinding of RNA secondary
structures and the remodeling of ribonucleoprotein particles
(RNPs) [1, 2]. RHs are classified into six known superfamilies
based on their sequence and structure [1]. Among these, the
large helicase superfamily 2 (SF2) contains more than 50
members in humans [3]. These are designated DDX and
DHX proteins based on the consensus amino acid sequence
DExD or DExH signature in their ATP-binding motif II
(Walker B motif) [3]. All SF2 RNA helicases are built around
a highly conserved helicase core region consisting of two do-
mains that resemble the bacterial recombination protein re-
combinase A (referred to as RecA-1 and RecA-2). Within
these two core helicase domains, eight highly conserved se-
quence elements, helicase core motifs (HCMs) play a role in
either RNA binding, or ATP binding and hydrolysis. The
roles of SF2 RNA helicases include regulation of splicing, nu-
clear mRNA export, translation, transcription, facilitation of
mRNA decay, microRNA processing, and cytoplasmic trans-
port and storage of RNAs [1]. So far, many of the RHs have
been studied in various cancers revealing the role of transla-
tion in carcinogenesis [4], and serve as potential biomarkers
for diagnosis and prognosis, and novel drug targets [5]. The
importance and functional relevance of certain SF2 RHs in
human neurodevelopment is demonstrated by the identifica-
tion of pathogenic germline variants in DDX3X [6], DDX6
[7], DHX30 [8], and DDX5 [9] in individuals with neurodeve-
lopmental disorders. Additionally, a paralog-based study im-
plicated a role for DHX16, DHX34, DHX37, and DDX54, in
human neurodevelopmental disorders and suggested that
DHX8, DDX47, and DHX58 may also be neurodevelopmen-
tal genes [10].
Previously, we reported 12 unrelated individuals with
global developmental delay (GDD), intellectual disability
(ID) accompanied by severe speech impairment and gait
abnormalities, harboring one of six different de novo mis-
sense variants located within highly conserved HCMs of
DHX30 [8]. Moreover, a recent study reported gonadal
mosaicism in two brothers carrying a de novo missense
variant, p.(Ser737Phe), which resides within a HCM [11].
Here, we performed clinical, genetic, and functional ana-
lyses to provide further understanding of DHX30-related
neurodevelopmental disorders through the identification
of 25 previously unreported individuals. This systematic
clinical and research approach, partially facilitated through
social media, establishes novel genotype-phenotype corre-
lations based on in-depth functional analyses accompanied
by clinical and genetic findings.
Methods
Human subjects and genetic analyses
Written informed consent for all 25 subjects was ob-
tained from the parents or legal guardians in accordance
with protocols approved by the respective ethics com-
mittees of the institutions involved in this study. Next-
generation sequencing-based analyses were performed in
various independent research or diagnostic laboratories
worldwide, using previously described procedures [8,
12–16]. Trio-whole exome sequencing (WES) was per-
formed in families of subjects 1, 4, 5, 6, 10, 11, 13, 14,
15, 17, 18, 19, 20, 21, 22, and 23. Single WES was per-
formed in subjects 2, 3, 8, 16, and 25. Targeted Sanger
sequencing was performed in subject 9, half-sister of
subject 8. For subject 7, WES was performed as duo with
DNA sample of his mother. Trio-whole genome
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sequencing (WGS) in family of the subject 12 was done
on an Illumina system using Nextera DNA Flex Library
Prep. Reads were aligned to human genome build
GRCh38 and analyzed for sequence variants using Cpipe
analysis tool [17]. Classification the identified variants
was based on the American College of Medical Genetics
and Genomics (ACMG) guidelines [18]. Clinical
Chromosomal Microarray analysis in family 24 was per-
formed using standardized platforms [19]. Interpretation
of identified copy number variants followed ACMG
guidelines [20]. Most individuals were enrolled in the
present study through the “DHX30 family support
group” on Facebook: https://www.facebook.com/
groups/1808373282809332. In such a case the families/
legal representatives were asked to provide the contact de-
tails of attending physicians in order to obtain objective
and accurate clinical and genetic data. Others presented in
the University Medical Center Hamburg-Eppendorf,
Hamburg, Germany, or were recruited through Gene-
Matcher [21] and our network of collaborators. For all 25
individuals, clinical data and information on genetic test-
ing were uniformly obtained from attending physicians
using a structured clinical summary (Additional file 1) and
clinical table (Additional file 2: Table S1).
Cell culture and in-vitro assays
Human embryonic kidney 293 T (HEK 293 T) cells and
human bone osteosarcoma epithelial (U2OS) cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) as de-
scribed previously [8]. DXH30 expression vectors based
on pEGFP-C3 (leading to an N-terminal GFP-tag) and
pEGFP-N2 (for expression of the mitochondrial form of
DHX30 with a C-terminal GFP-tag) have been described
previously [8]. Newly identified missense variants were in-
troduced into both vectors using Quick-Change II site-
directed mutagenesis kit (Agilent, Waldbronn, Germany).
HEK293T and U2OS cells were transfected with Turbo-
Fect or Lipofectamine 2000, respectively, transfection
reagent (ThermoFisher Scientific) according to the manu-
facturer’s recommendations. Immunocytochemistry and
puromycin incorporation assay in U2OS cells were per-
formed utilizing the following antibodies at manufacturers'
recommended dilutions: anti-Puromycin mouse monoclo-
nal (Millipore, #MABE343); goat anti-mouse coupled to
Alexa Fluor 555 (ThermoFisher Scientific). A custom
made anti-ATXN2 (#8G3, kindly provided by Dr. S. Kind-
ler, Human Genetics, UKE; Hamburg) rat monoclonal
antibody was used at a 1:10 dilution as previously de-
scribed [8]. ATPase assay was performed as previously de-
scribed [8]. Briefly, after transfection of HEK293T cells
with DHX30 expression vectors, followed by lysis in 1ml
of radioimmunoprecipitation assay buffer (RIPA), the ly-
sates were clarified by centrifugation at 20,000×g for 20
min at 4 °C. GFP-containing proteins were purified from
the supernatant by immunoprecipitation using 20 μl of
GFP-Trap_A matrix (Chromotek, Munich, Germany).
Precipitates were washed twice in RIPA buffer, and twice
in phosphate-free ATPase assay buffer (40mM KCl; 35
mM HEPES pH 7.5; 5 mM MgCl2; prepared in plastic
ware to avoid phosphate contamination). Precipitates were
then incubated in 50 μl phosphate-free buffer supple-
mented with 2mM ATP and 2mM DTT at 30 °C for 30
min (for assaying ATPase activity in the absence of ex-
ogenous RNA). After brief centrifugation (1min, 1000×g),
the supernatant was removed and precipitated samples
were incubated in phosphate-free buffer containing 2mM
ATP; 2mM DTT, and 100 μg/ml yeast RNA for 30min at
30 °C (for assaying ATPase activity in the presence of ex-
ogenous RNA). The amount of free phosphate released by
ATP hydrolysis was determined photometrically using
Biomol Green reagent (Enzo Life Sciences, Lörrach,
Germany). Subsequently, bead-attached proteins were de-
natured in SDS-sample buffer, and the amount of DHX30
protein was determined by western blotting using anti-
GFP (Covance). In each case, ATPase activity was normal-
ized to the amount of GFP-tagged DHX30 protein at-
tached to the GFP-trap matrix.
Helicase assay
6xHis-SUMO-DHX30 wild-type and mutant proteins
were expressed in the E. coli BL21 (DE3) pLysSpRARE
cells (Novagen, Germany). Proteins were purified from ly-
sates using Ni-NTA beads (Qiagen, Germany) as previ-
ously described [22]. To test the RNA unwinding activity
of DHX30, a [32P]-labeled RNA duplex was synthesized
using the T7 RNA polymerase from a linearized DNA
template designed by Tseng-Rogenski and Chang [23].
Helicase activity was measured in 20 μl of reaction mix-
ture containing 0.13 pmol of purified protein (=20 ng of
full-length protein), 25 fmol [32P]-labeled RNA duplex, 17
mM HEPES-KOH pH 7.5, 150mM NaCl, 1 mM MgCl2,
2mM DTT, 1mM spermidine, 0.3% PEG8000, 5% gly-
cerol, 150mM KCl, 20 units of RNasin™ Plus (Promega,
USA), 1 mM ATP. The mixture was incubated for 1 h at
37 °C, mixed with 2X non-denaturing loading dye and
subjected to gel electrophoresis through non-denaturing
8% PAGE (19:1) in 0.5X TBE at 4 °C. Reaction products
were visualized by autoradiography. For more information
see Additional file 1: Supplementary methods.
Generation of a HEK293T DHX30 stable knockout line
HEK293T DHX30-deficient cells were generated by
transfecting a plasmid (pLentiCRISPR v2, GenScript,
#52961) encoding a single guide RNA (CGAGTGCTAG
CTGATCGCTT) targeting exon 7, the Cas9 endonucle-
ase and a puromycin resistance gene under the control
of the EFS promoter. Cells were transfected with
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TurboFect transfection reagent (Thermo Scientific) and
treated with puromycin for 3 days. Surviving cells were
then subjected to single cell sorting using BD FACS
Aria™ IIIu Cell Sorter (BD Biosciences). Single-cell
clones were grown in 96-well plates for two weeks and
then expanded into 6 well dishes. DHX30 knockout effi-
ciency was assessed by Western blotting using an anti-
DHX30 rabbit polyclonal antibody (Bethyl, #A302-218A)
(1:500).
Stress treatment
HEK293T WT and DHX30-deficient cells were plated
on glass coverslips coated with poly-L-Lysine. After 24 h,
cells were heat stressed at 43.5 °C for 1 h, fixed in 4%
paraformaldehyde and permeabilized with 0.1% Triton
X-100 (Sigma). Blocking was performed using 10% horse
serum (HS). Rat monoclonal anti-ATXN2 was used as a
primary antibody (1:10 in 2 % HS in PBS), followed by
goat anti-rat IgG coupled to Alexa Fluor 647 (Thermo
Fisher Scientific). Coverslips were mounted on glass
microscope slides with ProLong Diamond Antifade
Mountant with DAPI (Thermo Fisher Scientific). Im-
munofluorescence images were acquired using a con-
focal microscope (Leica TCS SP5, 63x/1.25 objective)
and processed with ImageJ software.
Construction of Tol2 plasmids
DHX30 cDNA plasmids were assembled using the Tol2
MultiSite Gateway® kit (Invitrogen, USA). Briefly, the
cDNA of the wild-type DHX30 and DHX30 containing re-
spective missense variants were amplified from the
pEGFP-C3-DHX30 plasmids, using primers containing
the appropriate att site sequences for BP recombination
reactions. PCR products were purified and cloned into a
pDONR221 donor vector using BP Clonase II enzyme
mix following the manufacturer’s manual. The resulting
middle entry clones pME-DHX30 were purified and veri-
fied by direct sequencing. To assemble the final expression
plasmids, p5E-tuba1a promoter and pME-DHX30 were
cloned into a Tol2-based destination vector, pDest-
Tol2CG2 containing cmlc2:EGFP transgenesis marker,
using LR Clonase II Plus enzyme mix following the manu-
facturer’s instructions. The resultant pTol2pA2-cmlc2:
EGFP;tuba1a:DHX30 vectors were purified and verified by
direct sequencing.
Zebrafish maintenance and manipulation
Tol2 transposase mRNA were synthesized using mMES-
SAGE mMACHINE™ T7 Transcription Kit (Ambion)
per the manufacturer’s instructions. Twenty-five nano-
grams/μl Tol2 mRNA and 25 ng/μl of pTol2pA2-cmlc2:
EGFP;tuba1a:DHX30 DNA were injected into 1-cell
stage zebrafish embryos (Danio rerio AB strain). To in-
vestigate a potential dominant-negative effect, 25 ng/μl
Tol2 mRNA and 25 ng/μl equal mixture of pTol2pA2-
cmlc2:EGFP;tuba1a:DHX30 with the respective variant
DNA were injected into 1-cell stage zebrafish embryos.
The embryos were raised and scored for abnormal devel-
opment 1–7 days post fertilization. Zebrafish were
maintained in the Zebrafish Research Facility at the
University of Alabama at Birmingham using standard
protocols. All fish were maintained at 28 °C and kept at
14-h light and 10-h dark cycle under standard laboratory
conditions.
Generation of zebrafish dhx30 stable knockout line
The zebrafish dhx30 stable knockout line was generated
using CRISPR/Cas9 with sgRNA target sequence 5′-
TCAAGTTCAGCTGCACGGAT-3′ made by Integrated
DNA Technologies (IDT) according to the manufac-
turer’s protocol. The mutant contains an 8-bp deletion
that shifts the translational reading frame after amino
acid 90 and results in a premature stop codon at amino
acid 107, compared to 1173 amino acids for the wild-
type (WT) protein. Mutant animals were genotyped and
sequenced using primers 5′-ATCTTCACGCCAAAAA
CCTG-3′ and 5′-GACCACGGTTCAGCTCTCTC-3′.
The dhx30 heterozygous mutants were outcrossed to the
parental AB strain for at least two generations before
use in experiments to eliminate potential off-target vari-
ants. After each assay described below, test animals were
individually genotyped using PCR with primers 5′-
ATCTTCACGCCAAAAACCTG-3′ and 5′-GACC
ACGGTTCAGCTCTCTC-3′ and high-resolution melt-
ing (HRM) analysis as previously described [24].
Stress treatment and zebrafish whole-mount
immunostaining
The dhx30 +/− animals were in-crossed to generate
dhx30 +/+, +/−, and −/− sibling progeny for heat shock
and immunostaining analyses. Twenty-four-hour post-
fertilization embryos were dechorionated and incubated
at 28 °C or 42 °C for 1 h. After treatment, embryos were
fixed overnight in cold 4% paraformaldehyde (PFA). Em-
bryos were then dehydrated with acetone at − 20 °C for
7 min, washed in PBST [PBS+ 0.1% Tween 20], and
blocked with 10% goat serum for at least 1 h at room
temperature. Thereafter, embryos were incubated with
rabbit anti-TIAL-1 (Novus Biologicals, NBP1-79932; 1:
200) overnight at 4 °C, washed with PBST, and incubated
with secondary antibody Alexa Fluor 488-conjugated
goat anti-rabbit IgG (Invitrogen, A11034; 1:200) for 2 h
at room temperature. Embryos were washed with PBST,
incubated with 100 uM DAPI (1:500) to counterstain
nuclei for 10 min, and stored in PBS at 4 °C. For im-
aging, stained embryos were mounted in 1% low melting
agarose and imaged using a Nikon A1 inverted confocal
microscope at approximately 50-μm Z-stacks at 5.6 μm
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intervals. The number of TIAL-1-labeled stress granules
per 50 nuclei was quantified using Nikon NIS Element.
After imaging, test animals were individually genotyped
by PCR and HRM analysis to delineate the dhx30
genotype.
Behavioral assays
For each behavioral experiment, dhx30 +/− animals were
in-crossed to generate dhx30 +/+, +/−, and −/− sibling
progeny.
Twenty-four-hour sleep-wake activity
For each sleep-wake study, zebrafish larvae at 5-day
post-fertilization (dpf) were chosen randomly and placed
individually into each well of a flat-bottom 24-well plate.
The activity of each larva was tracked for 24 h consisting
of 14-h light and 10-h dark using the DanioVision sys-
tem (Noldus Information Technology). The average
swimming distance was measured for 24 h per 1-h time-
bins using EthoVision XT software (Noldus).
Social preference assay (SPA)
We adopted and modified a previously described social
preference assay (SPA) [25]. Briefly, SPA was performed
using a flat-bottom 12-well plate and custom-built re-
movable opaque dividers. The individual “test” animals,
whose behaviors were analyzed, were placed in each of
the 4 middle wells of the plate, and a WT conspecific of
similar age and size was placed in a well either above or
below each middle well. The activity of each test larva
was tracked using the DanioVision (Noldus Information
Technology) system and data analyzed using EthoVision
XT software (Noldus). Before data acquisition, animals
were given 5-min habituation period. The “baseline” ac-
tivity of the test fish was then recorded while the opaque
dividers were inserted between each well to prevent the
animals from seeing each other. The dividers were then
removed, allowing each test animal to view one well
containing a conspecific animal and one empty well. The
fish were given another 5-minute habituation period,
followed by a 10-min “post-baseline” recording. For data
analyses, wells containing test fish were divided into two
0.5 cm × 2.2 cm zones, one closest to the well containing
a conspecific animal and one closest to the empty well.
The amount of time spent by a test fish in each zone
during the baseline and post-baseline periods was ana-
lyzed. The social preference of each test fish was quanti-
fied by calculating the social preference index (SPI) =
(time spent in zone near the conspecific fish – time
spent in zone near the empty well)/time spent in both
zones as previously described [25].
Statistical analyses
All cell line data (U2OS and HEK293T) are presented as
mean ± SD and analyzed by One-Way ANOVA followed
by Dunnett’s multiple comparisons test or unpaired Stu-
dent’s t test as indicated in figure descriptions. All
zebrafish-related data are presented as mean ± SEM and
analyzed by unpaired Student’s t test. The percentage of
developmental defects observed upon overexpression of
dhx30 was analyzed by the χ2 test.
Results
Identification of likely causative variants in DHX30
We identified 25 individuals carrying likely causative
variants in DHX30 (Fig. 1). Of these, 12 individuals carry
a previously reported heterozygous missense variant lo-
calizing within highly conserved helicase core motifs
(HCMs): p.(Arg493His), p.(His562Arg), p.(Arg782Trp)
(5 individuals including two half-sisters indicative of go-
nadal mosaicism), p.(Arg785Cys) (4 individuals), and
p.(Arg785His). Further, 7 individuals have a novel het-
erozygous missense variant classified as either “likely
pathogenic” or “pathogenic” according to The American
College of Medical Genetics and Genomics (ACMG)
guidelines (Additional file 2: Table S1) [18]. Indeed, each
of these variants alters a highly conserved amino acid
within a HCM predicted to be responsible for ATP bind-
ing and/or hydrolysis (Fig. 1 and Additional file 3: Figure
S1). p.(Gly462Glu) identified in a single individual affects
motif I, also referred to as Walker A motif, that binds γ
phosphate and coordinates, together with motifs II and
VI, ATP binding and hydrolysis in other DExH family
members [26, 27]. p.(Ala734Asp) identified in two unre-
lated individuals, one of which (individual 6) appears to
have mosaicism for the variant (Additional file 4: Figure
S2), and p.(Thr739Ala) identified in a single individual,
both affect motif V which regulates both ATP binding
and/or hydrolysis and RNA binding [2, 27]. Three indi-
viduals carry p.(Arg782Gln), located within motif VI af-
fecting the identical arginine residue (Arg782), that we
previously reported p.(Arg782Trp) [8], which was identi-
fied here in five additional individuals.
Moreover, a homozygous variant p.(Arg725His) lo-
cated within the helicase core region albeit between mo-
tifs IV and V, unlike all the missense variants mentioned
above, was identified in individual 4 and classified as
“variant of uncertain significance”. Additionally, a het-
erozygous de novo variant p.(Arg908Gln) was identified
in individual 21. This was the only variant not located
within the helicase core region and was classified as
“likely pathogenic”. Predictions based on homology to
other SF2 helicases [26, 28] and published structures of
the Prp43 [29] and Mle [30] revealed three novel highly
conserved C-terminal regulatory domains (CTD). These
include a winged helix (WH), a ratchet-like (RL) and an
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oligosaccharide binding (OB) fold domain (Fig. 1) with a
potential role in coupling ATP hydrolysis to RNA un-
winding [31]. Notably, the p.(Arg908Gln) affects a highly
conserved residue within the RL domain (Figure S1).
Furthermore, we identified four individuals bearing
likely pathogenic loss-of-function variants. A heterozygous
de novo frameshift variant, p.(Ala116Valfs*12) in individ-
ual 22, a heterozygous nonsense variant, p.(Arg797*) in in-
dividual 23 inherited from a mosaic mother, and a de novo
in-frame deletion encompassing exons 7-9 of DHX30,
leading to deletion of 381 amino acids, in individual 25.
Individual 24 has a large heterozygous de novo deletion
(arr[GRCh37] 3p21.31 (47098509_48109065)del) encom-
passing ten genes including two disease genes previously
associated with an autosomal dominant inheritance,
SETD2 [32–34] and DHX30 (Fig. 1b and Additional file 5:
Figure S3), possibly pointing to a dual diagnosis. The
whole gene deletion results in haploinsufficiency, whereas
the in-frame deletion, frameshift, and nonsense variant, if
they were to result in stable proteins, are predicted to lead
to loss of functionally important domains (Fig. 1a).
Notably, none of these DHX30 alterations was present
in the gnomAD dataset v2.1.1 (Additional file 2: Table
S1) [35], indicating that they are extremely rare in the
population and unlikely to be variants unrelated to dis-
ease. As previously noted, DHX30 is one of the most
missense-intolerant genes in the human genome [8].
Furthermore, according to the gnomAD v2.1.1 dataset
DHX30 is, with a probability of being loss-of-function
intolerant (pLI) score of 1 and a loss-of-function ob-
served/expected upper bound fraction (LOEUF) score of
0.04, extremely loss-of-function intolerant [35]. Add-
itionally, the degree of intolerance to deleterious variants
of DHX30 according to the Residual Variation Intoler-
ance (RVI) score, which quantifies gene intolerance to
functional variants, is − 1.51 (3.54th percentile) and thus
even lower than the average RVI score for genes in-
volved in developmental disorders (0.56; 19.54th per-
centile) [36, 37].
Clinical spectrum of the DHX30-associated
neurodevelopmental disorders
All 19 individuals harboring a heterozygous missense
variant within a highly conserved motif in the helicase
core domain have global developmental delay (GDD), in-
tellectual disability (ID), severe speech impairment, and
gait abnormalities, similar to our initial findings [8]. In
more detail, all individuals had an intellectual disability,
only nine (47%) learned to walk, all with an ataxic gait.
The majority had no speech (74%), four individuals
spoke only single words, and only individual 6, who is
mosaic for the de novo p.(Ala734Asp) variant, spoke
simple sentences. It is worth noting that the individuals
highly benefit from communication devices (tablets,
smartphones, and eye-driven tablet communication sys-
tems) which significantly reduced frustration-related
Fig. 1 Location of identified DHX30 germline variants. a Highly conserved sequence motifs within the helicase core region are shown with color
coding that corresponds to the primary function of the motif (as previously described by Lessel et al., 2017). Double-stranded RNA-binding domains
(dsRBD) 1 and 2 at the N-terminus (N-) are shown in gray. A winged helix domain (WHD), a ratchet-like (RL) domain, and an oligosaccharide binding
(OB) domain are shown in yellow at the C-terminus (-C). The position of the first and last amino acid within each motif/domain is indicated below.
Previously reported heterozygous missense variants and newly identified DHX30 variants are denoted in gray and black, respectively. Frameshift and
nonsense variants are denoted in blue. Mutated amino acid residues within the helicase core region are marked in red. The position of previously and
newly identified variants are indicated with red arrows. b Genomic region, chr3.hg19:g.(47098509-48109065)del, of the ~ 1Mb deletion identified in
case 24
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behavior (D.L. personal communication with legal
guardians and family members). Additional phenotypic
features included muscular hypotonia in eighteen (95%),
feeding difficulties in sixteen (84%), microcephaly in
thirteen (81%, 13/16), joint hypermobility in fourteen
(74%), structural brain anomalies in eleven (65%, 11/17),
sleep disturbances in nine (47%), strabismus in eight
(42%), autistic features in five (33%, 5/15), and seizures
in four (21%) individuals (Table 1, Additional file 2:
Table S1 and Additional file 6). Noteworthy, individual 6
had a relatively milder clinical course, with a moderate
intellectual disability, independent walking at 2 years and
8months, and the ability to speak in simple sentences at
the age of 15 years. This individual´s presentation is
similar to that of the four individuals (#22, #23, #24, and
#25), who carry either a frameshift or nonsense variant,
whole-gene deletion or in-frame deletion, respectively,
who all learned to walk in the second year of life, had a
mild muscular hypotonia and spoke at least 20 words by
the age of 3 years. Although some individuals displayed
some dysmorphic features (Additional file 6) we did not
observe a recognizable facial gestalt, similar to our previ-
ous findings [8].
Two individuals (#4 and #21) clearly stand out pheno-
typically. Individual 4 was homozygous for p.(Arg725His),
developed early-onset infantile epileptic encephalopathy,
and died at 11months. In contrast, individual 21, who
harbors the de novo p.(Arg908Gln) variant, had unre-
markable psychomotor development until the age of 8
years when she presented with progressive balance impair-
ment with truncal ataxia. Subsequently, she experienced a
decline in motor skills and developed cognitive problems
with reduced concentration (Table 1, Additional file 2:
Table S1 and Additional file 6).
Effect of novel DHX30 missense variants on ATPase
activity
To corroborate the pathogenicity of the novel missense vari-
ants identified in this study, along with the recently reported
p.(Ser737Phe) [11], we performed several previously estab-
lished functional assays [8]. First, we analyzed the ATPase ac-
tivity of wild-type (WT) and mutant forms of DHX30. As






















variants within a HCM
(previous studies: Lessel
et al. 2017 and Cross et al.
2020)
Sex 11 females/7 males Female 1 female/3 males Male Female 8 females/6 males
Intellectual
disability
18/18 + 4/4 ? − 13/13













18/18 + 4/4 mild + − 14/14
Muscular
hypotonia






Ataxic gait 0/4 no independent
walking
3/4 ataxic gait




15/18 + 1/4 + − 11/14
Microcephaly 13/15 + 0/4 − − 7/10
Joint
hypermobility
13/18 + 1/3 − − 6/14
Brain MRI
anomalies
11/17 − 2/3 + + 10/14
Sleep
disturbance
8/18 + 2/3 + − 7/12
Strabismus 8/18 − 2/4 − + 6/14
Autistic
features
4/14 + 0/3 ? − 7/12
Seizures 3/18 + 2/3 Severe − 3/14
+, present; −, absent; ?, too young to evaluate; NA, unkown
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previously shown, DHX30-WT acts as an RNA-dependent
ATPase, and its ATPase activity is strongly stimulated by the
addition of RNA [8]. In contrast, and similar to the previ-
ously analyzed mutants [8] all missense variants (p.(Gly462-
Glu), p.(Arg725His), p.(Ala734Asp), p.(Ser737Phe),
p.(Thr739Ala), p.(Arg782Gln), and p.(Arg908Gln)) show a
significant reduction in ATPase activity in the presence of ex-
ogenous RNA (Fig. 2a). For control experiments, we included
two common non-synonymous DHX30 variants found in
public repositories [35]. Namely, p.(Val556Ile) is located
within the helicase core region albeit not within a HCM,
similar to p.(Arg725His), and p.(Glu948Lys) in the vicinity of
p.(Arg908Gln). Notably, in comparison to the missense vari-
ants identified in affected individuals, the ATPase activity
was not significantly reduced neither for p.(Val556Ile) nor
for p.(Glu948Lys) (Fig. 2b).
RNA helicase activity of DHX30 is disrupted by missense
variants within the helicase core motifs
DHX30 has been classified as an RH due to the presence
of the highly conserved motifs in its helicase core region
and sequence similarity to other RHs. To confirm that it
indeed possesses RNA helicase activity we established an
RNA unwinding assay for recombinant full-length
DHX30 purified from bacteria as a His6-SUMO-tagged
protein. As a substrate, we used a synthetic [32P]-labeled
RNA molecule which carries a sequence with a strong
propensity to self-anneal and form a double helix. Ana-
lysis of this RNA substrate by non-denaturing PAGE re-
sulted in a single band of low electrophoretic mobility,
corresponding to the dimer linked by the double helical
segment. This dimer could be resolved into a band of
higher mobility, the monomer, by pre-incubation at
96 °C (Fig. 2c). To identify the amount of the DHX30-
WT necessary to resolve the dimeric form we performed
a titration analysis from 1 to 160 ng. In the presence of
ATP, 10 ng of DHX30-WT was sufficient to resolve the
dimer into the monomeric form, confirming that
DHX30 indeed possesses the ATP-dependent RNA heli-
case activity (Fig. 2c and Additional file 7: Figure S4).
We next analyzed the impact of selected missense vari-
ants on the helicase activity, each affecting a different
helicase core motif (p.(Gly462Glu) in motif I,
p.(Arg493His) in motif Ia, p.(His562Arg) in motif II,
p.(Ser737Phe) in motif V, and p.(Arg785Cys) in motif
VI) along with p.(Arg908Gln) located in the RL domain.
All missense variants within a HCM failed to unwind
the RNA substrates in this assay, whereas the
p.(Arg908Gln) mutant behaved similarly to DHX30-WT
(Fig. 2d). It is worth noting that we subsequently failed
to purify the p.(Arg725His) mutant protein product.
This finding suggests misfolding of this mutant protein,
followed by either deposition of the insoluble protein in
inclusion bodies or its direct degradation [38]. Thus, we
could not analyze its impact on the helicase activity.
Subcellular localization and effect on global translation of
novel DHX30 missense variants
We have previously shown that the expression of mutant
forms of DHX30 induces the formation of stress gran-
ules, concomitant with a global down-regulation of
translation [8]. Therefore, we repeated this analyses for
selected novel missense variants. In keeping with the
previous results [8], we observed that mutants within a
HCM, p.(Gly462Glu), p.(Ala734Asp), p.(Ser737Phe), and
p.(Thr739Ala), also strongly accumulated in cytoplasmic
foci shown to be stress granules upon co-staining with
Ataxin-2 (ATXN2). Expression of the p.(Arg908Gln)
mutant, however, resulted in localization to cytoplasmic
aggregates that co-stained with Ataxin-2 in only 50% of
the transfected cells. In contrast, p.(Arg725His) was
mostly diffusely localized throughout the cytoplasm
similar to the DHX30-WT (Fig. 3 and Additional file 8:
Figure S5). Global translation was measured by incorp-
oration of puromycin into nascent peptide chains, which
were visualized with a puromycin-specific antibody.
Interestingly, expression of both the HCM mutants and
the p.(Arg908Gln) mutant resulted in dramatically de-
creased puromycin incorporation, suggestive of a global
decrease in protein synthesis (Fig. 3). Analogous to the
results obtained in the ATPase assay, the two common
variants p.(Val556Ile) and p.(Glu948Lys) were diffusely
localized throughout the cytoplasm, resembling the
DHX30-WT (Additional file 8: Figure S5).
In vivo analyses of selected DHX30 missense variants
Given the somewhat conflicting results of functional analyses
of the p.(Arg725His) and p.(Arg908Gln) variants, and in
order to gain a better understanding of the impact of DHX30
missense variants in vivo, we utilized a zebrafish model. Pre-
vious studies showed that overexpression of pathogenic al-
leles in zebrafish results in defective embryonic development
[39, 40]. Thus, we overexpressed human wild-type DHX30
cDNA or DHX30 cDNA harboring selected missense vari-
ants, p.(Arg493His), p.(Arg725His), p.(Arg785Cys), and
p.(Arg908Gln) as well as p.(Val556Ile) and p.(Glu948Lys) in
zebrafish using Tol2 transposition. Tol2 mRNA and
pTol2pA2-cmlc2:EGFP;tuba1a:DHX30 were co-injected into
1-cell stage zebrafish embryos. For analyses, we selected em-
bryos with strong cmlc2:EGFP expression which indicates a
high level of transgene integration in somatic cells. Overex-
pression of DHX30-WT, p.(Val556Ile) or p.(Glu948Lys) had
little or no impact on zebrafish embryonic development: over
88% of embryos displayed normal development and morph-
ology. However, expression of DHX30 harboring one of the
missense variants resulted in developmental defects in 75–
90% of embryos (Fig. 4 and Additional file 9: Figure S6),
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suggesting that these mutant alleles interfere with normal
embryonic development and supporting the pathogenicity of
p.(Arg725His) and p.(Arg908Gln).
Analyses of the nature of the DHX30 missense variants
Given the somewhat milder clinical presentation of indi-
viduals carrying a whole gene deletion, in-frame deletion,
frameshift, or nonsense variant as compared to the indi-
viduals harboring a de novo missense variant in one of the
HCMs, we further investigated the nature of the latter.
First, we analyzed the localization of the RFP-tagged
DHX30-WT co-expressed with respective GFP-tagged
missense variants. Notably, their equimolar expression re-
sulted in each case in DHX30-WT being localized in
Ataxin-2 positive cytoplasmic clusters (Fig. 5). These data
suggest that these missense variants either exert a domin-
ant negative effect on the wild-type or lead to a gain-of-
function since both overexpressed DHX30-WT and
Fig. 2 Protein variants of DHX30 affect ATPase and helicase activity. a, b ATPase assays were performed for DHX30-WT, novel DHX30 missense variants
(a), and two common polypmorphisms, p.(Val556Ile) and p.(Glu948Lys) (b) in the presence of exogenous RNA. ATPase activity was calculated by
subtracting phosphate values obtained with GFP alone from those obtained with GFP-tagged DHX30-WT and mutants. These figures were then
normalized on precipitated protein amounts using the intensities of the GFP signal in the western blot. Means ± standard deviation values are based
on 3 replications. **,***: significantly different from DHX30-WT, ns: not significantly different from DHX30-WT (**p< 0.01;***p< 0.001; n=3; One-Way
ANOVA, followed by Dunnett’s multiple comparisons test). Values were normalized on DHX30-WT ATPase activity obtained in the presence of RNA. c
Increasing amounts of His6-SUMO-tagged DHX30 WT protein were incubated with a
32P-labeled RNA substrate in the presence (lane 3–7) or absence
(lane 8) of ATP and analyzed by native PAGE. The position of the RNA duplex and the single-stranded RNA are indicated in the first and second lanes,
respectively. Their schematic representation is shown at the right side. d Helicase assay was repeated for selected DHX30 missense variants affecting
either conserved motifs within the helicase core region (lane 4–8) or the auxiliary RL domain (lane 9)
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endogenous DHX30 are recruited to cytoplasmic clusters
only after stress [8].
Next, we analyzed if the DHX30-WT can rescue the
inability of p.(Arg493His), p.(His562Arg), and
p.(Arg785Cys) to unwind RNA. The addition of DHX30-
WT to p.(His562Arg) and p.(Arg785Cys) efficiently re-
solved the dimer into the monomeric form even in the
presence of increased amounts of the respective mu-
tants. However, we observed only a partial rescue when
DHX30-WT was added to the p.(Arg493His) variant
(Fig. 6a). Our data suggest that the mutants cause a loss
of helicase function rather than having a dominant nega-
tive effect. Given these somewhat contradictory results,
we turned again to the zebrafish model. We co-injected
pTol2pA2-cmlc2:EGFP;tuba1a:DHX30 p.(Arg493His) or
p.(Arg785Cys) with wild-type DHX30 cDNA and
assessed embryonic development. Interestingly, co-
injection of DHX30-WT, at a similar level, partially
rescued the abnormal phenotypes associated with both
p.(Arg493His) and p.(Arg785Cys) (Fig. 6b), a finding that
could potentially support both loss-of-function and a
dominant negative effect as a mechanism underlying
disease.
DHX30 deficiency impairs stress granules formation in
HEK293T cells and zebrafish
To further characterize the role of DHX30 we estab-
lished HEK293T DHX30 stable knockout lines. CRISPR/
Cas9 based knockout (KO) of DHX30 in HEK293T cells
yielded several cell lines with a residual DHX30 immu-
noreactivity of less than 10 % (Fig. 7). Given that
DHX30 is recruited to SGs, we wondered whether
DHX30 additionally plays a role in SG formation. There-
fore, we assessed the ability of KO cells to induce SGs or
cytoplasmic clusters following heat stress treatment. By
incubating cells at 43.5 °C, a condition after which en-
dogenous DHX30 accumulates in SGs [8], we observed
that KO cells had a significantly reduced number of SG-
positive cells as compared to HEK293T WT cells (Fig.
7). These data suggest a previously unknown role of
DHX30 in SG assembly. Combined with our previous
findings (Fig. 3 and 5) these data actually suggest that
the HCM missense variants exhibit a gain of function by
triggering SG formation which results in global transla-
tion inhibition.
Next, we generated a predicted null allele in the single
zebrafish dhx30 ortholog using CRISPR/Cas9. At day
five post fertilization, transcript levels of dhx30 were
barely detectable in homozygous mutant animals com-
pared to wild-type, whereas heterozygous siblings
Fig. 3 Missense variants in DHX30 initiate the formation of cytoplasmic
aggregates and impair global translation. Puromycin incorporation assay in
U2OS cells expressing DHX30-GFP fusion proteins (green). Translation was
monitored by staining against puromycin (red), SGs were detected by
ATXN2 (magenta) and nuclei via DAPI staining (blue). Arrows indicate
transfected cells. Note the correlation between formation of clusters and















Normal/Survived Dead at 4dpf Dead at 5dpf
Dead at 6dpf Dead at 7dpf
**** **** **** ****
Fig. 4 Protein variants of DHX30 lead to embryonal developmental
defects in zebrafish. In vivo analyses of selected DHX30 missense
variants. Assessment of embryonic development after injection of
DHX30 WT and mutant cDNAs in a zebrafish model. Bar graph
indicating the percentage of cmcl2-GFP positive zebrafish embryos
assessed 4–7 days post fertilization (dpf). The presented data are
derived from three independent studies. The total number of
embryos assessed are 45, 23, 21, 30, 34, 33, and 29 for WT, V556I,
E948K, R493H, R725H, R785C, and R908Q, respectively. ****:
significantly different from WT (****p< 0.0001; χ2 test)
Mannucci et al. Genome Medicine           (2021) 13:90 Page 10 of 19
displayed ~ 30% lower dhx30 expression as compared to
wild type, potentially due to nonsense mediated decay of
the mutated alleles (Additional file 10: Figure S7). The
homozygous mutant animals are viable, fertile, and mor-
phologically indistinguishable from their wild-type and
heterozygous siblings (data not shown). Previous studies
have demonstrated that during early embryonic develop-
ment, zebrafish exhibit robust SG formation in response
to stress, such as heat shock [41]. Therefore, based on
our in vitro findings, we first asked whether dhx30 mu-
tant zebrafish also exhibit impaired SG formation
in vivo. At 24-h post-fertilization and normal condition,
compared to dhx30-WT the homozygous mutant exhib-
ited significantly lower number of SGs, determined by
staining for TIAL-1, an established stress granule marker
(Fig. 8). Although an increase in SG formation occurred
upon heat shock, the number of TIAL-1-labeled SGs
remained significantly lower in the homozygous mutants
compared to sibling controls (Fig. 8). Thus, these data
show that SG formation is compromised in the homozy-
gous mutants and suggests an evolutionarily conserved
role for DHX30 in SG assembly.
Dhx30-deficient zebrafish display altered behavioral
activity
We next examined whether dhx30-deficient zebrafish
exhibit abnormal sleep-wake activity and social behav-
iors, similar to those recently observed in a zebrafish
Fig. 5 Recombinant protein variants of DHX30 induce translocation of the DHX30-WT in the cytoplasmic clusters. Immunocytochemical detection of
RFP-DHX30 WT (red) and ATXN2 (magenta) after co-expression of DHX30-GFP mutants (green) in U2OS cells. Bar graph indicating the percentage of
cells where RFP-DHX30 WT co-localizes with DHX30-GFP mutants within cytoplasmic clusters identified as SGs via co-staining with ATXN2 (****:
significantly different form DHX30-WT: **** p < 0.0001; n > 100 from 3 independent transfections; one-way ANOVA followed by Dunnett’s multiple
comparisons test). Scale bars indicate 10 μm
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model of the NR3C2-related neurodevelopmental dis-
order [25]. We first analyzed sleep-wake behaviors in 5-
day-old dhx30 KO mutants. Compared to wild-type and
heterozygous siblings, the homozygous mutants dis-
played significantly less activity during the day and more
nocturnal activity (Fig. 9a–c), mimicking somewhat the
sleep disturbances in individuals affected by a DHX30-
related neurodevelopmental disorder. Additionally, using
an established social preference assay, we observed that
the wild-type and heterozygous animals showed the pre-
viously described social behavior of preferring to stay
close to conspecific fish of similar age and size, whereas
the homozygous animals did not show this preference
(Fig. 9d–e). There were no obvious dysmorphic pheno-
types in the homozygous mutant animals compared to
their wild-type and heterozygous siblings. We propose,
therefore, that the mutant phenotype was not simply
due to developmental delay but influenced by abnormal-
ities in complex neural circuitry. Taken together, our
data indicate that dhx30 KO zebrafish have a social be-
havioral deficit with altered sleep-wake activity, which is
consistent with findings in DHX30-related neurodeve-
lopmental disorders.
Discussion
Our study has allowed further delineation of the clinical
spectrum of DHX30-related neurodevelopmental disor-
ders through analysis of 25 novel affected individuals,
partially facilitated by the use of a social media-based
family support group. Individuals harboring heterozy-
gous missense variants affecting highly conserved resi-
dues within a HCM present with global developmental
delay, intellectual disability, muscular hypotonia, severe
gait abnormalities (if walking is acquired), and remain
non-verbal or speak only single words. We also identi-
fied microcephaly as an additional common feature. In-
dividuals with either a mosaic missense variant within a
HCM, or with variants resulting in haploinsufficiency or
with protein-truncating variants all learned to walk in
the second year of life, had a mild muscular hypotonia,
and spoke at least 20 words by the age of 3 years. There-
fore, based on the clinical and molecular findings we
Fig. 6 Analyses of the nature of missense variants within the helicase core motifs (HCM). a RNA unwinding activity of purified DHX30 R493H, H562R,
and R785C mutants was analyzed upon addition of DHX30 WT protein. Increasing amounts of mutant proteins were incubated with 20 ng of WT
protein and assayed for their ability to unwind a radiolabeled RNA duplex in the presence of ATP. b Assessment of embryonic development after co-
injection of DHX30 R493H and R785C with DHX30 WT cDNA in a zebrafish model. Bar graph indicating the percentage of cmcl2-GFP positive zebrafish
embryos 4–7 days postfertilization (dpf). The presented data are derived from three independent studies. The total number of embryos assessed are
58, 43, and 51 for WT, R493H+WT, and R785C+WT, respectively. ****: significantly different from WT (****p< 0.0001; χ2 test)
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suggest a classification in two DHX30-associated neuro-
developmental disorder subtypes.
It is worth noting that the identified heterozygous
deletion in individual 24 also encompasses the first
15 SETD2 exons, suggestive of a dual diagnosis. How-
ever, given the phenotypic differences in the seven in-
dividuals reported to date, some of whom inherited
their SETD2 variant from an apparently unaffected
parent [32–34], we are unsure to what extent loss of
SETD2 contributed to the phenotype observed in this
individual.
Identification of affected individuals with milder
phenotype challenges naming of this disorder “Neurode-
velopmental disorder with severe motor impairment and
absent language” (NEDMIAL; OMIM # 617804). Not-
ably, only 9 of the 25 individuals (36%) presented here
had a severe motor impairment (never learned to walk)
and 9 out of 25 individuals (36%) spoke at least single
words, thus did not have a completely absent language.
Therefore, we suggest referring to these conditions as
DHX30-associated neurodevelopmental disorders in the
future.
To provide further evidence for the pathogenicity of
the novel DHX30 variants and gain better insight into
the genotype-phenotype correlation we performed sev-
eral in vitro and in vivo analyses. For this, we have now
formally confirmed that DHX30 possesses ATP-
dependent RNA helicase activity. In line with their ab-
sence from public databases and high evolutionary con-
servation of affected amino acid residues, all novel
missense variants within a HCM resulted in impaired
ATPase activity (all were within an ATP binding and hy-
drolysis motif), impaired helicase activity, and showed an
increased propensity to trigger stress granule (SG) for-
mation resulting in inhibition of global translation, as
expected from the previous study [8]. In addition,
Fig. 7 DHX30 deficiency in HEK293T cells leads to reduced formation of stress granules. a Immunocytochemical detection of endogenous ATXN2
(magenta) in WT HEK293T cells and DHX30-deficient HEK293T cells before (left panel) and after (right panel) heat shock at 43.5 °C for 1 h. Note
that, upon heat stress and depletion of DHX30 (right hand, lower panel), ATXN2 does not alter its diffuse cytoplasmic distribution to accumulate
in cytoplasmic foci, as observed in WT HEK293T cells (right hand, upper panel). Nuclei are identified via DAPI staining (blue). Scale bars indicate
10 μm. b Bar graph indicating the percentage of cells containing stress granules. (*: significantly different from WT HEK293T cells: *p< 0.05; n >
200 from 3 independent experiments; unpaired t test ). c Western blotting detection of DHX30 knock-out efficiency in HEK293T cells. Expression
of DHX30 was reduced by 90% as detected by a DHX30 specific antibody. Tubulin was used as loading control
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selected HCM missense variants interfere with normal
zebrafish embryonic development.
We have previously suggested that the missense vari-
ants within HCM might have a more severe effect than a
loss of one gene copy [8]. This hypothesis is now sup-
ported by identification of four affected individuals car-
rying variants that result in either haploinsufficiency or a
truncated protein, all of whom presented with a milder
phenotype as compared to the individuals harboring
missense variants within HCM. To gain further insight
into the nature of these variants we determined that
DHX30-WT can rescue the inability of selected HCM
missense variants to unwind an RNA duplex, and that
co-injection of DHX30-WT with selected HCM mis-
sense variants can partially ameliorate the observed zeb-
rafish phenotypes. These data point to loss-of-function
effects of the HCM mutants on a molecular level. How-
ever, co-expression of HCM missense variants together
Fig. 8 DHX30 deficiency in zebrafish cells leads to reduced formation of
stress granules. a Representative confocal images of TIAL-1-labeled stress
granules (green) in dhx30 wild-type (+/+) and homozygous mutants (−/−).
Zebrafish underwent normal conditions or heat shock treatment at 42 °C.
Nuclei were counterstained with DAPI (blue). b Analyses of TIAL-1-labeled
stress granules per 50 nuclei. The total number of embryos assessed are 8,
9, 8, and 8 for dhx30 +/+ (28 °C), dhx30 −/− (28 °C), dhx30 +/+ (42 °C), and
dhx30 −/− (42 °C), respectively. Data are presented as means ± standard
error of mean based on the indicated number of embryos. ***: significantly
different from DHX30+/+ (***p<0.001; unpaired Student’s t test)
Fig. 9 Behavioral analyses of dhx30 mutant zebrafish. a Distance
moved of dhx30 mutants and wild-type sibling controls measured at
5 days post fertilization. b Average of distance moved during 14-h
daytime. c Average of distance moved during 10-h nighttime. N =
15, 18, and 25 for +/+, +/−, and −/− animals, respectively. d Social
preference index (SPI) calculated during 10-min baseline and post-
baseline period. SPI = 1 indicates a fish that spends 100% of its time
near a conspecific, SPI = − 1 indicates a fish that spends 100% of its
time near the empty well, and SPI = 0 indicates a fish that spends
equal amounts of time near the conspecific and near the empty
well. e The change in SPI between baseline and post-baseline,
indicating the preference of zebrafish to stay close to conspecific
fish. N = 13, 6, and 17 for +/+, +/−, and −/− animals, respectively.
Data are presented as means ± standard error of mean based on
the indicated number of embryos. *: significantly different from
dhx30+/+ (*p< 0.05; unpaired Student’s t test)
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with the DHX30-WT resulted in recruitment of
DHX30-WT into SG´s, a finding that might possibly
suggest a dominant negative effect. It is worth noting
that DHX30-WT, as well as the endogenous protein, are
recruited to the SG´s after stress induction [8]. Thus,
HCM missense variants might actually result in a detri-
mental gain-of-function by inducing SG formation with
concomitant global translation impairment even without
endogenous or exogenous stressors.
To gain further clarity we focused on the relation of
DHX30 to SG formation. Using CRISPR/Cas9 based
technology, we established two DHX30 knockout
models. Analyses of both, DHX30-deficient HEK293T
cells and zebrafish, revealed an impairment of SG forma-
tion upon heat stress, pointing to an essential and evolu-
tionary conserved role of DHX30 in SG assembly. These
findings provide a molecular explanation for the above-
mentioned phenotypic differences, as they strongly sug-
gest that pathogenic missense HCM variants, in addition
to the loss of ATPase or RNA-binding activity and with
impaired helicase function, exert a selective gain-of-
function by triggering SG formation. This is in line with
our hypothesis that due to SG hyper-assembly these
pathogenic variants generate a chronic condition of im-
paired translation [8]. Noteworthy, impaired translation
due to aberrant SG formation is associated with a broad
variety of neurodegenerative and neurodevelopmental
diseases [8, 42]. Furthermore, repeat expansion under-
lying C9orf72-associated neurodegenerative disorders
has recently been suggested to result in chronic cellular
stress due to aberrant SG formation [43].
Beyond providing the molecular explanation for the
genotype-phenotype correlation of these two subtypes
we additionally performed in vivo behavioral modeling
of zebrafish dhx30 KO’s. Zebrafish exhibit all the hall-
marks of mammalian sleep by utilizing neurotransmit-
ters known to coordinate sleep and wake states in
humans [44]. Analysis of dhx30-deficient animals re-
vealed a compromised sleep/wake behavior, as they were
less active during the day but more active and slept less
at night than dhx30-WT animals. This is partially remin-
iscent of the sleep disturbances observed in almost half
of DHX30-affected individuals. Additionally, homozy-
gous dhx30 KO animals displayed altered social behavior
as manifested by their performance in the social prefer-
ence assay, e.g., showing reduced preference for conspe-
cifics as compared to dhx30-WT zebrafish. The
observed social behavioral deficits and altered sleep-
wake activity are similar to the findings in zebrafish
models of other neurodevelopmental disorders [25, 45],
and to some extent recapitulate the clinical findings in
individuals affected by the DHX30-related neurodevelop-
mental disorder.
Furthermore, we present here two individuals who
clearly stand out both in terms of their clinical presenta-
tion and their identified DHX30 variant. Individual 4
with an early-lethal infantile epileptic encephalopathy
carries a homozygous missense variant, p.(Arg725His),
and individual 21 with a de novo p.(Arg908Gln) variant
shows late-onset progressive ataxia. Trio-WES analysis
performed in both individuals identified these DHX30
variants as the only candidates (Supplementary Data). As
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these variants occurred outside the HCM motifs, we in-
cluded two similarly located common non-synonymous
DHX30 variants found in gnomAD, p.(Val556Ile) and
p.(Glu948Lys), in our functional analysis for comparison.
However, these two latter variants behaved similarly to
DHX30-WT in all assays performed (Table 2).
For the variant p.(Arg725His), located within the heli-
case core region but not within a HCM, we observed a
reduced ATPase activity. However, unlike HCM mis-
sense variants it does not trigger SG hyper-assembly.
When attempting to analyze its impact on the helicase
activity we consistently failed to purify the p.(Arg725His)
mutant protein product. We therefore suggest that this
biallelic variant leads to a loss-of-function, likely due to
misfolding. The fact that it was inherited from un-
affected heterozygous parents indicates that its effect is
somewhat milder as compared to the variants identified
here resulting in haploinsufficiency or protein-
truncation, and that similar heterozygous missense vari-
ants may not contribute to disease.
The de novo missense variant p.(Arg908Gln) affects a
highly conserved residue within the RL domain. This
variant impairs the ATPase but not helicase activity of
DHX30, suggesting that the RL domain is required for
the coupling of helicase activity to ATP hydrolysis.
Whereas this variant leads to formation of aberrant cyto-
plasmic aggregates, which cannot be eliminated by co-
expression of DHX30-WT, not all of these aggregates/
foci could be confirmed to be translationally silent SGs.
The functional characterization of both variants identi-
fied differences to HCM missense variants, which may
potentially explain the genotype-phenotype correlation.
Additionally, both individuals presented with clinical
signs and symptoms observed in other affected individ-
uals, suggestive of a phenotypic continuum. We cannot
exclude, however, the possibility that they carry add-
itional variants with phenotypic consequences, which
were undetected by trio-whole exome sequencing. Iden-
tification of similarly affected individuals carrying similar
variants is required to establish their causality.
Conclusions
The identification of 25 affected individuals has ex-
panded the clinical and genetic spectrum of the DHX30-
associated neurodevelopmental disorder. Our data sug-
gest the existence of clinically distinct subtypes correlat-
ing with location and nature of pathogenic variants. Our
study highlights the usefulness of social media-based
family support groups as a resource in defining ultra-
rare disorders as well as the need for in-depth functional
characterization of potentially pathogenic variants to
understand their biological consequences. We confirmed
that DHX30 is an ATP-dependent RNA helicase, and
showed that DHX30 is essential for stress granule
assembly in cellular and in vivo models. Missense vari-
ants in helicase core motifs lead to a loss of ATPase and
helicase activity, concomitant with a gain-of-function
with respect to SG formation, and a severe phenotype.
In contrast, DHX30 loss-of-function variants are associ-
ated with a milder phenotype. Additional studies are re-
quired to further delineate the variety of clinical
outcomes underlying different DHX30 variants as well as
the roles of DHX30 in various aspects of RNA
metabolism.
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